Apellis制药 APLS 深 沪
交易中 01-28 11:02:32 美东时间
22.955
+1.145
+5.25%
华盛通- 最 高23.79
- 今 开22.53
- 成交量 178.76万股
- 最 低 22.14
- 昨 收 21.81
- 总市值 29.15亿
- 52周最高 30.48
- 市盈率 静 --
- 换手率 1.41%
- 52周最低 16.10
- 委 比 -61.24%
- 总股本 1.27亿
- 历史最高 94.75
- 量 比 3.74
- 振 幅 7.57%
- 历史最低 11.45
- 每 手 1
- 风险率 3.78%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Apellis, Olema, Exicure, Immunovant, LivePerson Insider Shake-Up
Insiders have been trading these 5 stocks: (($APLS)), (($OLMA)), (($XCUR)), (($...
01-24 21:01
美股大行评级 | 奈飞绩后遭13家大行下调目标价；齐昂银行、美国合众银行获多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从9美元升至50美元；韦德布什：维持Ardelyx, Inc."跑赢大市"评级，目标价从16美元升至19美元
01-22 15:09
Apellis CEO Cedric Francois Reports Disposal of Common Shares
Apellis CEO Cedric Francois Reports Disposal of Common Shares Cedric Francois, Chief Executive Officer and Director of Apellis Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by
01-22 05:15
Apellis Pharmaceuticals General Counsel David Watson Reports Disposal of Common Shares
Apellis Pharmaceuticals General Counsel David Watson Reports Disposal of Common Shares David O. Watson, General Counsel of Apellis Pharmaceuticals Inc., reported a disposal of common shares of Apellis Pharmaceuticals Inc. The full filing can be accessed through the link below. Disclaimer: This news
01-22 05:08
Apellis Valuation Ignores Empaveli Potential, Says Analyst
BofA upgraded Apellis to Buy, citing strong early Empaveli uptake, FDA approval in rare kidney disease, and long-term sales upside.
01-22 02:14
U.S. RESEARCH ROUNDUP-IBM, KLA, WEX
U.S. RESEARCH ROUNDUP-IBM, KLA, WEX Jan 21 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including IBM, KLA and WEX, on Wednesday. HIGHLIGHTS * IBM IBM.N : JP Morgan raises target price to $312 from $290 * KLA Corp KLAC.O : Deut
01-21 16:26
美股大行评级 | 存储再获大行看好！花旗、瑞银和美银齐上调西部数据、希捷科技等公司目标价；PNC金融服务获6家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Soleno Therapeutics"买入"评级，目标价从110美元升至120美元；富国银行：维持Soleno Therapeutics"超配"评级，目标价从106美元升至114美元
01-21 11:42
Wells Fargo Maintains Overweight on Apellis Pharmaceuticals, Lowers Price Target to $26
Wells Fargo analyst Derek Archila maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Overweight and lowers the price target from $29 to $26.
01-20 23:46
美股周涨跌榜 | 算力基建再提速！Galaxy Digital 涨超37%，获批电力容量翻番；创新药企IBRX大涨近137%
算力基建再提速！Galaxy Digital 周涨超37%，获批电力容量翻番；创新药企IBRX周涨近137%，在研创新药获批上市>>
01-17 10:31
美股大行评级 | 高盛上调谷歌目标价从330美元升至375美元；5家大行集体上调Five Below目标价最高至255美元
今日重点评级关注：HC Wainwright & Co.：维持NioCorp Developments"买入"评级，目标价从9.5美元升至11.25美元；摩根士丹利：维持Chewy"超配"评级，目标价从48美元升至51美元
01-14 11:25
